2021-2032 All Rights Reserved. Online Journal of Veterinary Research . You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the  before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to OJB publications. This article may be copied once but may not be, reproduced or  re-transmitted without the express permission of the editors. This journal satisfies the refereeing requirements (DEST) for the Higher Education Research Data Collection (Australia). Linking:To link to this page or any pages linking to this page you must link directly to this page only here rather than put up your own page.


OJVRTM

 Online Journal of Veterinary Research 

 Volume 25 (5): 350-353, 2021.


Effect of Remdesivir and Chloroquine on hypertensive ACE drugs in COVID 19 patients.

 

Tayseer Shaker Mahmood

 

Department of Nursing, Al-Hadi University College, Baghdad, Iraq

 

ABSTRACT

 

Mahmood TS., Effect of Remdesivir and Chloroquine on hypertensive ACE drugs in COVID 19 patients, Onl J Vet Res., 25 (5): 350-353, 2021. Coronaviruses of single sense strand RNA genome are enveloped viruses infecting humans and animals responsible for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and SARS-CoV2 COVID-19 responsible for worldwide pandemic with ~2M deaths to date. To manage hypertension, patients are given angiotensin converting enzyme receptor blockers (ACE) but there is scant information of possible interaction with COVID 19 treatments. Potential therapies for COVID 19 before severe symptoms are manifested include hydroxychloroquine, chloroquine phosphate, remdemsivir, ivermectin and lopinavir/ritonavir with or without zinc. Hypertensive COVID 19 patients using ACE receptor inhibitors are at increased risk by enhancing ACE2 blockers in epithelial cells lining the lung, where SARS-CoV-2is more likely to infect these cells via ACE2 receptors. Similarly, ACEI and ARBs drugs are shown to interact with several antiretroviral drugs leading to increase viral load. Chloroquine has an antagonistic effect with remdesivir which leads to decrease therapeutic activity of remdesivir. These results highlight possible risk of combination therapies with ACEI and ACE2.

 

Keyword: COVID-19, SARS, Remdesivir, Chloroquine, Antagonism, ACEI.


MAIN

 

FULL-TEXT (SUBSCRIBE OR PURCHASE TITLE